Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares were down 5% on Tuesday . The stock traded as low as $6.63 and last traded at $6.79. Approximately 2,041,821 shares changed hands during trading, an increase of 76% from the average daily volume of 1,157,640 shares. The stock had previously closed at $7.15.

Several research analysts have recently weighed in on TTPH shares. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. BMO Capital Markets reaffirmed a “buy” rating and set a $12.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 15th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 price target on the stock. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $11.21.

The stock’s market cap is $346.65 million. The company’s 50 day moving average is $6.46 and its 200-day moving average is $7.21.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. During the same quarter last year, the business posted ($0.47) EPS. The firm’s revenue was up 28.2% compared to the same quarter last year. On average, equities research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post ($2.54) earnings per share for the current year.

In related news, insider Jacques Dumas sold 7,155 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.50% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its holdings in shares of Tetraphase Pharmaceuticals by 3.4% in the 1st quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 6,114 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Tetraphase Pharmaceuticals by 6.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 7,866 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Tetraphase Pharmaceuticals by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after purchasing an additional 230,420 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 17.0% in the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 45,554 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Tetraphase Pharmaceuticals by 180.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 408,078 shares during the last quarter. Institutional investors own 41.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/05/tetraphase-pharmaceuticals-inc-ttph-stock-price-down-5.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.